Medistep Healthcare IPO GMP: Day 1 IPO Live Updates

Posted by : sachet | Fri Aug 08 2025

Medistep Healthcare IPO GMP: Day 1 IPO Live Updates

The Medistep Healthcare IPO GMP is ₹17 as of 8th August 2025. It is a bookbuilding IPO of ₹16.10 crores and comprising a fresh issue of 37.44 lakh shares. The issue will be listed on NSE and SME on its tentative listing date, 18th August 2025. The face value of Medistep Healthcare shares stands at ₹10 per share, and the IPO price is set at ₹43 per share. Retail investors can bid for a minimum of 2 lots of 6,000 shares worth ₹2,58,000.

Medistep Healthcare IPO GMP Grey Market Premium

As of 8th August 2025, Medistep Healthcare IPO GMP stands at ₹17 per share. Thus, the estimated listing price would be ₹60. This indicates that the estimated listing gain in this IPO could be 39.53%. However, GMP details are subject to change based on market conditions and fluctuations. Explore the table for the Medistep Healthcare IPO GMP updates.

GMP DateIPO PriceGMPEstimated Listing Price Estimated Listing Gains
08-08-2025₹43.00₹17.00₹60.0039.53%
07-08-2025₹43.00₹17.00₹60.0039.53%
06-08-2025₹43.00₹12.00₹55.0027.91%
05-08-2025₹43.00₹12.00₹55.0027.91%

Medistep Healthcare IPO Details

IPO Open Date8th August 2025
IPO Close Date12th August 2025
IPO Allotment Date13th August 2025
Refund Initiation 14th August 2025
Issue Size37,44,000 shares(aggregating up to ₹16.10 Cr)
Face Value₹10 per share
Lot Size3,000 Shares
Issue Price Band₹43 per share
Issue TypeFixed Price IPO
Listing AtNSE & SME
Listing Date18th August 2025

Explanation

Medistep Healthcare IPO: Medistep Healthcare Limited has declared an issue price of ₹43 per share. With this IPO, the company allows retail investors to bid for at least 2 lots of 6,000 shares worth ₹2,58,000. The face value of Medistep Healthcare Limited shares is ₹10 per share. The shares of Medistep Healthcare Limited will be listed on NSE and SME on its tentative listing day, 18th August 2025. Scroll down to check GMP updates and Medistep Healthcare IPO reviews. 

Objectives of the Medistep Healthcare IPO

The primary aim of the Medistep Healthcare IPO is to raise ₹16.10 crores. On the other hand, Medistep Healthcare has decided to utilise these funds in different ways. Explore some of the secondary objectives for the Medistep Healthcare IPO.

  • To meet the general corporate purpose.
  • To prepayment or repayment of borrowings availed by the company.
  • To meet the general corporate requirements.
  • Funding the capital expenditure towards the purchase of plant and machinery for expansion at the existing facility.

Medistep Healthcare IPO Registrar

Cameo Corporate Services Limited is the registrar of the Medistep Healthcare IPO, waiting to manage the IPO allotment procedure and refund initiation. For any queries regarding the Medistep Healthcare allotment and refund, you can contact Cameo Corporate Services Limited at cameo@cameoindia.com or +91-44-28460390.

Medistep Healthcare IPO Review

The Medistep Healthcare IPO has gained neutral ratings from industry experts, brokers, and institutional investors. Medistep Healthcare Limited’s revenue increased by 27% from ₹39.08 crores in March 2024 to ₹49.66 crores in March 2025. Moreover, the company’s PAT increased by 25% from ₹3.33 crores to ₹4.14 crores. Investors can analyse other relevant factors and make a decision accordingly.

Most analysts recommend applying for this IPO to diversify your investment portfolio in the stock market. However, we’re waiting for further ratings to have a better idea and will keep posting them to deliver real-time insights. Until then, you can explore the company’s technical analysis to know whether you should apply for the Medistep Healthcare IPO or not.

Medistep Healthcare Limited Technicals

Key IndicatorsValue
PE Ratio (Price-to-Earnings) 10.86
EPS (Earnings Per Share)3.96
RoNW29.06%
ROCE38.91%
ROE29.06%
EBITDA Margin11.27%
Price to Book Value2.67
Market Capitalisation₹61.10 Cr

The PE ratio of Medistep Healthcare Limited shares is 10.86, and its Earnings Per Share (EPS) stands at 3.96. Thus, the Medistep Healthcare IPO can potentially deliver gains on its tentative listing date, 18th August 2025. 

Note: The data, as mentioned above, is taken from authentic sources and highlights pre-issue information. The PE ratio and EPS of Medistep Healthcare Limited are subject to change after the IPO. Explore the table below to get post-issue updates on these two metrics. 

IndicatorsPre-IPOPost-IPO
PE Ratio10.8614.74
EPS 3.962.92

Medistep Healthcare Peer Comparison

Company Name EPSP/E RatioRoNWFace valueRevenue
Medistep Healthcare Limited3.9610.8624.62₹1031.63
Fabino Enterprises Limited0.2989.863.12₹1021.39
Achyut Healthcare Limited0.02200.501.77₹16.86

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Also Read : Knowledge Realty Trust REIT IPO GMP & Review: Apply or Avoid?

FAQs on Medistep Healthcare IPO

What is the Medistep Healthcare IPO GMP?

Ans. Currently, on 8th August 2025, the Medistep Healthcare IPO GMP (Grey Market Premium) stands at ₹17. This indicates that the estimated listing price could be ₹60 per share.

What is the issue price of the Medistep Healthcare IPO?

Ans. The Medistep Healthcare IPO price is set at ₹43 per share. Retail investors can apply for a minimum of 2 lots consisting of 6,000 shares worth ₹2,58,000. Moreover, HNIs are required to bid for a minimum of 3 lots (9,000 shares) worth ₹3,87,000.

Who is the registrar of the Medistep Healthcare IPO?

Ans. Cameo Corporate Services Limited is the registrar of the Medistep Healthcare IPO, waiting to manage the IPO allotment procedure and refund initiation. For any queries regarding the Medistep Healthcare allotment and refund, you can contact Cameo Corporate Services Limited at cameo@cameoindia.com or +91-44-28460390.

Disclaimer: The above information is compiled from authentic sources and is just for informational purposes. To have detailed information about the Medistep Healthcare IPO, download the Medistep Healthcare IPO RHP and Medistep Healthcare IPO DRHP. Conduct your research before investing in IPOs to avoid significant losses. You can also consult your financial advisor.

Recent Articles

Essex Marine IPO GMP & Review: Apply or Avoid?

BLT Logistics IPO GMP & Review: Apply or Avoid?

RR Kabel Q1 Results FY26: Q1 PAT Jumps 39.44% to ₹89.77 Crore; Revenue Surged 13.85% YoY

Kirlosker Brothers Q1 Results FY26: Q1 PAT Soars 2.46% to ₹66.70 Crore; Revenue Declined 5.03% YoY

Aaradhya Disposal IPO GMP & Review: Apply or Avoid?

Aarti Industries Q1 Results FY26: Q1 PAT Down 68.61% to ₹43.00 Crore; Revenue Declined 9.45% YoY

icon

100% Safe & Secure Platform.

Univest encrypts all data and transactions to ensure a completely secure experience for our members.

Copyright

2025 Univest. All rights reserved. | Designed with ❤️ in India
About Univest
About: Univest is a cutting-edge stock market platform designed to help traders and investors maximize their returns with expert-driven advisory services and seamless trading execution. Whether you're a seasoned trader or just starting, Univest simplifies your investment journey with actionable trade recommendations, AI-powered portfolio insights, and a fully integrated brokerage experience. With Univest, you gain access to proven stock market advisory, offering expert trade ideas for stocks, futures, options, and commodities. Our one-click trade execution feature eliminates slippage, ensuring instant execution through our advisory-first brokerage. Smart portfolio management allows you to identify underperforming stocks, optimize your investments, and receive real-time alerts. Additionally, Univest provides seamless investment opportunities beyond stocks, including mutual funds, bonds, fixed deposits, and insurance (coming soon). Join over 40 lakh active investors who trust Univest to make informed and profitable trading decisions. Start investing smarter today! 🚀  
Attention Investors : To ensure a smooth trading experience and prevent unauthorized transactions, investors must update their mobile number and email ID with their stockbroker or depository participant. As per regulatory requirements, investors are required to pay a stipulated amount as an upfront margin for trading in the Cash/FO segment. We encourage all investors to regularly check their securities in the Consolidated Account Statement (CAS) issued by depository to verify their holdings.Always verify alerts and transaction details received directly from the exchange or NSDL before proceeding with any trades. Please do not make payments through unverified email links, WhatsApp, or SMS. Always trade through a registered stockbroker and verify all details before making financial decisions.
 
Disclaimer: Investments in the securities market are subject to market risks. Please read all related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit. For more disclaimer /disclosure, visit https://univest.in/stock-broker or Univest App.We collect and use your contact information for legitimate business purposes, including providing updates on our products and services. We do not sell or rent your contact information to third parties. By submitting your details, you authorize us to contact you via Call/SMS, even if you are registered under DND. This authorization remains valid for 12 months.For grievances, please contact us at hello@unibrokers.in .
 
Univest Stock Broking Disclosures
Univest Stock Broking Private Limited - SEBI Reg. No. INZ000317437 (Stock Broker), NSE TM Code: 90392, BSE TM Code: 6866, MCX TM Code: 57290 and ICCL- Self Clearing Member Code: 6866, SEBI Reg. No. IN-DP-779-2024 (Participant), NSDL DP ID: IN304748.
 Risk Disclosures on Derivatives
1. 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
2. On an average, loss makers registered net trading loss close to ₹ 50,000
3. Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
4. Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Attention Investors: As per NSE circular dated July 6, 2022: https://nsearchives.nseindia.com/content/circulars/INSP52900.pdf, BSE circular dated July 6, 2022: https://www.bseindia.com/markets/MarketInfo/DispNewNoticesCirculars.aspx?page=20220706-55, MCX circular dated July 11, 2022: https://www.mcxindia.com/docs/default-source/circulars/english/2022/july/circular-418-2022.pdf?sfvrsn=9401991_0, investors are cautioned to abstain them from dealing in any schemes of unauthorised collective investments/portfolio management, indicative/ guaranteed/fixed returns / payments etc. 
Investors are further cautioned to avoid practices like:
a. Sharing 
i) trading credentials – login id and passwords including OTPs.
ii) trading strategies,
iii) position details.
b. Trading in leveraged products /derivatives like Options without proper understanding, which could lead to losses.
c. Writing/ selling options or trading in option strategies based on tips, without basic knowledge and understanding of the product and its risks.
d. Dealing in unsolicited tips through platforms like Whatsapp, Telegram, Instagram, YouTube, Facebook, SMS, calls, etc.
e. Trading / Trading in “Options” based on recommendations from unauthorised / unregistered investment advisors and influencers.
 Kindly read the Advisory Guidelines For Investors as prescribed by the Exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client’s assets: https://nsearchives.nseindia.com/content/circulars/INSP49434.pdf
Kindly, read the advisory as prescribed by the Exchange with reference to their circular: NSE/ISC/51035 dated January 14, 2022 regarding Updation of mandatory KYC fields by March 31, 2022: https://www.nseindia.com/resources/exchange-communication-circulars# 
Attention Investors: Prevent unauthorised transactions in your Demat account by updating your mobile number with your depository participant. Receive alerts on your registered mobile number for debit and other important transactions in your Demat account directly from NSDL on the same day. Prevent unauthorised transactions in your Trading account by updating your mobile numbers/email addresses with your stock brokers. Receive information on your transactions directly from the Exchange on your mobile/email at the end of the day. Issued in the interest of investors. KYC is a one-time exercise while dealing in securities markets - once KYC is done through a SEBI-registered intermediary (Broker, DP), you need not undergo the same process again when you approach another intermediary. As a business, we don’t give stock tips and have not authorised anyone to trade on behalf of others. If you find anyone claiming to be part of Univest Stock Broking Private Limited and offering such services, please send us an email at hello@unibrokers.in
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account.
Update your email ID and mobile number with your stockbroker/depository participant and receive an OTP directly from the depository on your registered email ID and/or mobile number. Check your securities/mutual funds/bonds in the Consolidated Account Statement (CAS) issued by NSDL every month.
Attention Investors: SEBI has established an Online Dispute Resolution Portal (ODR Portal) for resolving disputes in the Indian Securities Market. This circular streamlines the existing dispute resolution mechanism, offering online conciliation and arbitration, benefiting investors and listed companies https://www.sebi.gov.in/legal/circulars/jul-2023/online-resolution-of-disputes-in-the- indian-securities-market_74794.html. ODR portal for Investors - https://smartodr.in/login.
Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.
General
arrow down